Cemsidomide vs Lenalidomide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline
Cemsidomide
Developed by C4 Therapeutics, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07280013 (registry estimate)
No aligned efficacy figure on record for this race.
Lenalidomide
Marketed by Bristol-Myers Squibb and partners
NCT00056160 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled Phase 3 trial enrolled 353 patients with previously treated multiple myeloma and used a hard clinical primary endpoint, time to tumor progression. The primary comparison was met: median TTP was 60.1 weeks (95% CI 41.1–80.0) with lenalidomide plus dexamethasone versus 20.1 weeks (95% CI 16.1–21.1) with placebo plus dexamethasone, a large, clearly favorable separation. The trial's strong design and positive primary result make this high-quality evidence for lenalidomide.
Next expected readout: November 2026 · NCT06505369 (registry estimate)
Reported efficacy
Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months); Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008) (From randomization up to cut-off date of 02 March 2008; up to 51 months): Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7) (met)
Result source: NCT00424047
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cemsidomide | Lenalidomide |
|---|---|---|
| PFS, median | —Not reported | 35.3 vs 21.8+13.5 vs placeboNCT0185052413 other results
|
| OS, median | —Not reported | 39.3 vs 31.5+7.8 vs placeboNCT000561608 other results
|
| ORR | —Not reported | 78.5% vs 65.5%vs Lenalidomide + DexamethasoneNCT0123979712 other results
|
| VGPR or better | —Not reported | 75.8% vs 44.2%vs Lenalidomide, Low-dose DexamethasoneNCT020760091 other result
|
| MRD negativity | —Not reported | 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT036520645 other results
|
PFS, median
- Cemsidomide
- —Not reported
- Lenalidomide
- 35.3 vs 21.8+13.5 vs placeboNCT01850524
13 other results
- 31.4 vs 29.5 NCT01335399
- 19.4 vs 14.8 NCT01239797
- 26.3 vs 17.6 NCT01080391
- 25.5 vs 21.2 NCT00689936
- 20.7 vs 21.2 NCT00689936
- 26 vs 21.9 NCT00689936
- 21 vs 21.9 NCT00689936
- 31.4 vs 12.9 NCT00405756
- 14.3 vs 12.9 NCT00405756
- 19.4 vs 14.9 NCT01239797
- 45.3 vs 29.6 NCT02252172
- 25.9 NCT00405756
- 7.5 NCT00405756
OS, median
- Cemsidomide
- —Not reported
- Lenalidomide
- 39.3 vs 31.5+7.8 vs placeboNCT00056160
8 other results
- 37.4 vs 30.8 NCT00424047
- 67.6 vs 51.8 NCT02076009
- 90.3 vs 64.1 NCT02252172
- 60.4 vs 57.6 NCT01335399
- 48.3 vs 39.6 NCT01239797
- 48.3 vs 40.4 NCT01080391
- 59.1 vs 49.1 NCT00689936
- 62.3 vs 49.1 NCT00689936
ORR
- Cemsidomide
- —Not reported
- Lenalidomide
- 78.5% vs 65.5%vs Lenalidomide + DexamethasoneNCT01239797
12 other results
- 82.5% NCT03859427
- 86.3% NCT03859427
- 82% vs 80% NCT01850524
- 92.9% vs 76.4% NCT02076009
- 92.9% vs 81.6% NCT02252172
- 87.1% vs 66.7% NCT01080391
- 75.1% vs 62.3% NCT00689936
- 73.4% vs 62.3% NCT00689936
- 80.7% vs 67.5% NCT00689936
- 78.6% vs 67.5% NCT00689936
- 91.7% vs 75% NCT02252172
- 62.5% NCT00928486
VGPR or better
- Cemsidomide
- —Not reported
- Lenalidomide
- 75.8% vs 44.2%vs Lenalidomide, Low-dose DexamethasoneNCT02076009
1 other result
- 81.5% vs 56.9% NCT02252172
MRD negativity
- Cemsidomide
- —Not reported
- Lenalidomide
- 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT03652064
5 other results
- 60.9% vs 39.4% NCT03652064
- 59% vs 50% NCT01850524
- 32.1% vs 11.1% NCT02252172
- 18.9% NCT03859427
- 18.1% NCT03859427
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Cemsidomide: no structured comparison results are available for Multiple Myeloma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Cemsidomide: 0 of 4 rows · Lenalidomide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lenalidomide |
|---|---|
| Dropout rate | 63.8%a NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 show 33 more results— NCT00424047 · Phase 3 · combination n/a: no completion milestone NCT03652064 · Phase 3 · registry result, not featured evidence — NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 n/a: no completion milestone NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 n/a: no completion milestone NCT02252172 · Phase 3 · registry result, not featured evidence · combination 16.2%20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 49.3%Ixazomib + LenDex NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0.8% NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0.6% NCT01239797 · Phase 3 · registry result, not featured evidence · combination 0% NCT02322320 · Phase 3 · registry result, not featured evidence 0% NCT01109004 · Phase 3 · registry result, not featured evidence 1% NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Lenalidomide and Dexamethasone (Rd NCT00689936 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneLenalidomide and Dexamethasone Rd1 NCT00689936 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneLenalidomide and Low-Dose Dexameth NCT00689936 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneMPR+R NCT00405756 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneMPR+p NCT00405756 · Phase 3 · registry result, not featured evidence · combination 0% NCT01621672 · Phase 3 · registry result, not featured evidence —Lenalidomide ( ExtensionPhase) 22 NCT00622336 · Phase 3 · registry result, not featured evidence —Lenalidomide (Treatment Phase) Up NCT00622336 · Phase 3 · registry result, not featured evidence —Lenalidomide and Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneLenalidomide+Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination 40% NCT00928486 · Phase 3 · registry result, not featured evidence · combination 56.4% NCT00420849 · Phase 3 · registry result, not featured evidence · combination 51.3% NCT00478777 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT00179647 · Phase 3 · registry result, not featured evidence 0% NCT02969837 · Phase 2 · registry result, not featured evidence — NCT02619682 · Phase 2 · registry result, not featured evidence 6.1% NCT03477539 · Phase 2 · registry result, not featured evidence 5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 19.8%a NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 show 33 more results— NCT00424047 · Phase 3 · combination — NCT03652064 · Phase 3 · registry result, not featured evidence — NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 — NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 — NCT02252172 · Phase 3 · registry result, not featured evidence · combination —20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —Ixazomib + LenDex NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0% NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0% NCT01239797 · Phase 3 · registry result, not featured evidence · combination — NCT02322320 · Phase 3 · registry result, not featured evidence — NCT01109004 · Phase 3 · registry result, not featured evidence — NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Lenalidomide and Dexamethasone (Rd NCT00689936 · Phase 3 · registry result, not featured evidence · combination 13.1%Lenalidomide and Dexamethasone Rd1 NCT00689936 · Phase 3 · registry result, not featured evidence · combination 12.7%Lenalidomide and Low-Dose Dexameth NCT00689936 · Phase 3 · registry result, not featured evidence · combination 20.4%MPR+R NCT00405756 · Phase 3 · registry result, not featured evidence · combination 17.6%MPR+p NCT00405756 · Phase 3 · registry result, not featured evidence · combination — NCT01621672 · Phase 3 · registry result, not featured evidence —Lenalidomide ( ExtensionPhase) 22 NCT00622336 · Phase 3 · registry result, not featured evidence —Lenalidomide (Treatment Phase) Up NCT00622336 · Phase 3 · registry result, not featured evidence —Lenalidomide and Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination —Lenalidomide+Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination 8% NCT00928486 · Phase 3 · registry result, not featured evidence · combination 18.2% NCT00420849 · Phase 3 · registry result, not featured evidence · combination 19.3% NCT00478777 · Phase 3 · registry result, not featured evidence · combination 15.4% NCT00179647 · Phase 3 · registry result, not featured evidence — NCT02969837 · Phase 2 · registry result, not featured evidence — NCT02619682 · Phase 2 · registry result, not featured evidence — NCT03477539 · Phase 2 · registry result, not featured evidence — NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 62.7%a NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 show 33 more results59.7% NCT00424047 · Phase 3 · combination 72.1% NCT03652064 · Phase 3 · registry result, not featured evidence — NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 72.4% NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 79.4% NCT02252172 · Phase 3 · registry result, not featured evidence · combination 37.7%20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 32.5%20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —Ixazomib + LenDex NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 65.4%Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 73%Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 79% NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 74.8% NCT01239797 · Phase 3 · registry result, not featured evidence · combination 6.7% NCT02322320 · Phase 3 · registry result, not featured evidence 20.6% NCT01109004 · Phase 3 · registry result, not featured evidence 65.3% NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 57%Lenalidomide and Dexamethasone (Rd NCT00689936 · Phase 3 · registry result, not featured evidence · combination —Lenalidomide and Dexamethasone Rd1 NCT00689936 · Phase 3 · registry result, not featured evidence · combination 71.1%Lenalidomide and Low-Dose Dexameth NCT00689936 · Phase 3 · registry result, not featured evidence · combination 44%MPR+R NCT00405756 · Phase 3 · registry result, not featured evidence · combination 40.8%MPR+p NCT00405756 · Phase 3 · registry result, not featured evidence · combination 72% NCT01621672 · Phase 3 · registry result, not featured evidence 23.8%Lenalidomide ( ExtensionPhase) 22 NCT00622336 · Phase 3 · registry result, not featured evidence 53.6%Lenalidomide (Treatment Phase) Up NCT00622336 · Phase 3 · registry result, not featured evidence 42.7%Lenalidomide and Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination —Lenalidomide+Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination 48% NCT00928486 · Phase 3 · registry result, not featured evidence · combination 57.9% NCT00420849 · Phase 3 · registry result, not featured evidence · combination 54.9% NCT00478777 · Phase 3 · registry result, not featured evidence · combination 45.9% NCT00179647 · Phase 3 · registry result, not featured evidence 39.1% NCT02969837 · Phase 2 · registry result, not featured evidence 13.3% NCT02619682 · Phase 2 · registry result, not featured evidence 26.5% NCT03477539 · Phase 2 · registry result, not featured evidence 22.5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a fatigue 64.4% (placebo 60%) neutropenia 49.2% (placebo 6.9%) diarrhoea 48% (placebo 30.3%) NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 show 27 more resultsconstipation 40.3% (placebo 23.4%) neutropenia 40.3% (placebo 9.7%) diarrhoea nos 38.1% (placebo 25.7%) NCT00424047 · Phase 3 · combination diarrhoea 56.3% peripheral sensory neuropathy 55.8% neutropenia 54.8% NCT03652064 · Phase 3 · registry result, not featured evidence neutropenia 65.4% diarrhoea 59.7% upper respiratory tract infection 43.5% NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 diarrhoea 65.1% neutropenia 61.5% fatigue 44.8% NCT02252172 · Phase 3 · registry result, not featured evidence · combination 20/56 mg/m^2 once weekly neutropenia 29.1% anaemia 25.1% hypertension 21.5% NCT03859427 · Phase 3 · registry result, not featured evidence · combination 20/27 mg/m^2 twice weekly neutropenia 31.6% hypertension 24.2% anaemia 23.8% NCT03859427 · Phase 3 · registry result, not featured evidence · combination diarrhoea 77% (placebo 30%) oedema peripheral 55.5% (placebo 32.5%) constipation 48.2% (placebo 38.1%) NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 diarrhoea 41.7% (placebo 30%) oedema peripheral 40.5% (placebo 32.5%) constipation 36.2% (placebo 38.1%) NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 diarrhoea 51.8% fatigue 49.3% oedema peripheral 43.9% NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 diarrhoea 50% fatigue 48.4% anaemia 42.5% NCT01239797 · Phase 3 · registry result, not featured evidence · combination diarrhoea 43.4% anaemia 42.3% neutropenia 40.1% NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 constipation 38.9% diarrhoea 38% anaemia 35.4% NCT00689936 · Phase 3 · registry result, not featured evidence · combination diarrhoea 46.6% anaemia 44.5% constipation 43.8% NCT00689936 · Phase 3 · registry result, not featured evidence · combination neutropenia 78% thrombocytopenia 68.7% anaemia 66% NCT00405756 · Phase 3 · registry result, not featured evidence · combination neutropenia 76.3% thrombocytopenia 65.8% anaemia 59.9% NCT00405756 · Phase 3 · registry result, not featured evidence · combination grade 1 hypoalbuminemia 68% grade 1 thrombocytopenia 52% grade 2 leukopenia 36% NCT01621672 · Phase 3 · registry result, not featured evidence asthenia 14.3% headache 14.3% anaemia nos 9.5% NCT00622336 · Phase 3 · registry result, not featured evidence fatigue (asthenia, lethargy, malaise) 77.1% hemoglobin 64.6% glucose, serum-high (hyperglycemia) 55.2% NCT00064038 · Phase 3 · registry result, not featured evidence · combination neutropenia 80% lymphopenia 64% leukopenia 60% NCT00928486 · Phase 3 · registry result, not featured evidence · combination fatigue 42.4% neutropenia 41.4% muscle spasms 34.4% NCT00420849 · Phase 3 · registry result, not featured evidence · combination muscle spasms 24.3% fatigue 22.9% leukopenia 19.4% NCT00478777 · Phase 3 · registry result, not featured evidence · combination fatigue 56% neutropenia 32.3% muscle cramp 25.6% NCT00179647 · Phase 3 · registry result, not featured evidence fatigue 63% diarrhea 45.7% edema limbs 37% NCT02969837 · Phase 2 · registry result, not featured evidence lymphocyte decreased 36.7% lymphocyte decreased 33.3% wbc decreased 33.3% NCT02619682 · Phase 2 · registry result, not featured evidence platelet count decreased 93.9% anemia 91.8% neutrophil count decreased 83.7% NCT03477539 · Phase 2 · registry result, not featured evidence lymphocyte count decreased 85% neutrophil count decreased 77.5% white blood cell decreased 72.5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 26 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lenalidomide
show 7 more results
show 12 more results
show 11 more results
show 1 more result
show 3 more results
show 13 more results
show 1 more result
show 9 more results
show 7 more results
+ 128 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemsidomide's landscape · Lenalidomide's landscape